Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: Insights from ACCORD, ADVANCE, and VADT

Current Cardiology Reports

Volumn 14, Issue 1, 2012, Pages 79-88

  Terry, Toni ^a   Raravikar, Kalyani ^a   Chokrungvaranon, Nalurporn ^b   Reaven, Peter D ^a,c,d  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

ACCORD; ADVANCE; Advanced glycation end products; Atherosclerosis; Coronary artery calcium; Diabetes duration; Glycated hemoglobin; Hypoglycemic unawareness; Intensive glycemic control; Macrovascular disease; Metabolic memory; Microvascular disease; Type 2 diabetes; UGDP; UKPDS; VADT

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMORBIDITY; DIABETIC ANGIOPATHY; DIABETIC DIET; DIABETIC MACROANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MACROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT RESPONSE;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84857631399     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0238-6     Document Type: Article

References (33)

1. S Wild G Roglic A Green, et al. 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047 1053 15111519 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
2. M Hanefeld S Fischer H Schmechel, et al. 1991 Diabetes intervention study: multi-intervention trial in newly diagnosed NIDDM Diabetes Care 14 308 317 2060433 10.2337/diacare.14.4.308 1:STN:280:DyaK3M3osVOqsw%3D%3D
3. M Wei SP Gaskill SM Haffner 1998 Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study Diabetes Care 21 1167 1172 9653614 10.2337/diacare.21.7.1167 1:STN:280:DyaK1czhslCqtA%3D%3D (Pubitemid 28368527)
4. PW Wilson LA Cupples WB Kannel 1991 Is hyperglycemia associated with cardiovascular disease? The Framingham Study Am Heart J 121 586 590 1990765 10.1016/0002-8703(91)90729-2 1:STN:280:DyaK3M7hvVyntA%3D%3D
5. JM Sprafka GL Burke AR Folsom 1991 Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey Diabetes Care 14 537 543 1914792 10.2337/diacare.14.7.537 1:STN:280:DyaK38%2FgslSguw%3D%3D
6. AS Jaffe JJ Spadaro K Schechtman, et al. 1984 Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus Am Heart J 108 31 37 6731279 10.1016/0002-8703(84)90541-6 1:STN:280:DyaL2c3ivVWqsA%3D%3D (Pubitemid 14087965)
7. Meinert CL, Knaterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. II. Mortality results. Diabetes 1970, 19:Suppl:789-830.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
10. R Holman S Paul M Bethel, et al. 2008 10-Year Follow-up of intensive glucose control in type 2 diabtes N Engl J Med 359 1577 1589 18784090 10.1056/NEJMoa0806470 1:CAS:528:DC%2BD1cXht1Wgt7nK This article contains the 10-year follow-up of intensive glucose control in type 2 diabetes for the UKPDS
11. A Ceriello K Esposito M Ihnat, et al. 2009 Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes J Clin Endocrinol Metab 94 2751 2756 19491221 10.1210/jc.2009-0762 1:CAS:528:DC%2BD1MXpvFGntr0%3D
12. A Ceriello M Ihnat J Thorpe 2009 Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94 410 415 19066300 10.1210/jc.2008-1824 1:CAS:528:DC%2BD1MXhvFCqs7Y%3D
13. A Ceriello 2009 Hypothesis: the "metabolic memory", the new challenge of diabetes Diabetes Res Clin Pract 86 Suppl 1 S2 S6 20115927 10.1016/S0168-8227(09)70002-6 1:CAS:528:DC%2BD1MXhsFyksLjL
14. Intensive diabetes treatment and cardiovasculoar disease in patients with type 1 diabetes. The diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. N Engl J Med 2005, 353:2643-2653.
15. •• Effects of intensive glucose lowering in type 2 diabetes. The action to control cardiovascular risk in diabetes study group. N Engl J Med 2008, 358:2545-2559. This article contains the data from the ACCORD trial.
16. M Riddle 2010 Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial Circulation 122 844 846 20733112 10.1161/CIRCULATIONAHA.110.960138
17. M Riddle W Ambrosius D Brillon, et al. 2010 Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial Diabetes Care 33 983 990 20427682 10.2337/dc09-1278
18. •• Long-term effects of intensive glucose lowering on cardiovascular outcomes. The ACCORD study group. N Engl J Med 2011, 364:818-828. This article contains the 5-year outcomes from the ACCORD trial.
19. S Meguro T Shigihara Y Kabeya, et al. 2009 Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects Intern Med 48 657 663 19420810 10.2169/internalmedicine.48. 1865
20. S Sayage R Estacio B Jeffers, et al. 1996 Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM Diabetes Care 19 1243 1248 10.2337/diacare.19.11.1243 (Pubitemid 26363440)
21. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE collaborative group. N Engl J Med 2008, 358:2560-2572.
22. • Woodward M, Patel A, Zoungas S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Diabetes Care publish ahead of print, published online October 4, 2011. This article shows that irrespective of absolute risk, the effects of intensive glycemic control with the gliclazide modified release-based regimen used in ADVANCE were similar across Asia, established market economies, and eastern Europe and can be safely recommended for patients with type 2 diabetes in all these regions.
23. W Duckworth C Abraira T Moritz, et al. 2009 Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 129 139 19092145 10.1056/NEJMoa0808431 1:CAS:528:DC%2BD1MXnsFWkug%3D%3D This article contains the data from the VADT trial
24. L Agrawal N Azad N Emanuele, et al. 2011 Observation on renal outcomes in the veterans affairs diabetes trial Diabetes Care 34 2090 2094 21775749 10.2337/dc11-0175 This article shows that intensive glucose control had no significant effect on the progression of renal disease but was associated with some protection against increasing microalbuminuria in certain individuals
25. Duckworth W, Abraira C, Moritz T, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Presented at the June 2009 annual meeting of the ADA in New Orleans, LA.
26. P Reaven T Moritz D Schwenke, et al. 2009 Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis Diabetes 58 2642 2648 19651816 10.2337/db09-0618 1:CAS:528:DC%2BD1MXhsVCht7%2FP These data indicate that intensive glucose lowering reduces cardiovascular events in those with less extensive calcified coronary atherosclerosis
27. A Goldin J Beckman A Schmidt, et al. 2006 Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 597 605 16894049 10.1161/CIRCULATIONAHA.106.621854 1:CAS:528: DC%2BD28Xns1Snu70%3D (Pubitemid 44199649)
28. S Yan R Ramasamy A Schmidt 2010 The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature Circ Res 106 842 853 20299674 10.1161/CIRCRESAHA.109.212217 1:CAS:528:DC%2BC3cXjs1aku7w%3D
29. R Boussageon T Bejan-Angoulvant M Saadatian-Elahi, et al. 2011 Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials BMJ 343 d4169 10.1136/bmj.d4169 21791495 10.1136/bmj.d4169 This is the largest and most recent met-analysis to examine whether intensive glucose lowering affects all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes
30. FM Turnbull C Abraira RJ Anderson, et al. 2009 Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2288 2298 19655124 10.1007/s00125-009-1470-0 1:CAS:528:DC%2BD1MXht1Cis7jI This is another recent, large meta-analysis that suggests that participants who do not have a history of macrovascular disease may benefit from more intensive glycemic control
31. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research goup. N Engl J Med 1993, 329:977-986.
32. •• Standards of Medical Care in Diabetes-2011. American Diabetes Association. Diabetes Care 2011, 34:S11-S61. These are the most recent guidelines published by the American Diabetes Association.
33. P Gaede P Vedel N Larsen, et al. 2003 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383 393 12556541 10.1056/NEJMoa021778 (Pubitemid 36159355)